These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26662360)

  • 1. Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence.
    Greenberg WM; Citrome L
    Neurol Ther; 2015 Dec; 4(2):81-91. PubMed ID: 26662360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone for the treatment of schizoaffective disorder.
    Alphs L; Fu DJ; Turkoz I
    Expert Opin Pharmacother; 2016; 17(6):871-83. PubMed ID: 26934062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder.
    Chue P; Chue J
    Ther Clin Risk Manag; 2016; 12():109-16. PubMed ID: 26869795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].
    Bellantuono C; Santone G
    Riv Psichiatr; 2012; 47(1):5-20. PubMed ID: 22358213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.
    Macaluso M; Oliver H; Sohail Z
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):871-879. PubMed ID: 28675307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
    Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
    J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paliperidone: a review of clinical trial data and clinical implications.
    Wang SM; Han C; Lee SJ; Patkar AA; Pae CU; Fleischhacker WW
    Clin Drug Investig; 2012 Aug; 32(8):497-512. PubMed ID: 22747259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of paliperidone extended-release in treatment of schizoaffective disorder.
    Canuso CM; Turkoz I; Fu DJ; Bossie CA
    Neuropsychiatr Dis Treat; 2010 Oct; 6():667-79. PubMed ID: 20957127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.
    Emsley R; Kilian S
    Neuropsychiatr Dis Treat; 2018; 14():205-223. PubMed ID: 29379293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invega Hafyera (Paliperidone Palmitate): Extended-Release Injectable Suspension for Patients With Schizophrenia.
    Peters L; Dyer M; Schroeder E; D'Souza MS
    J Pharm Technol; 2023 Apr; 39(2):88-94. PubMed ID: 37051282
    [No Abstract]   [Full Text] [Related]  

  • 16. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling D; Schooler N; Lindenmayer JP; Canuso C; Alphs L
    J Clin Psychopharmacol; 2016 Aug; 36(4):372-6. PubMed ID: 27322760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
    Girardi P; Del Casale A; Rapinesi C; Kotzalidis GD; Splendori F; Verzura C; Trovini G; Sorice S; Carrus D; Mancinelli I; Comparelli A; De Filippis S; Francomano A; Ballerini A; Marcellusi A; Mennini FS; Ducci G; Sani G; Pompili M; Brugnoli R
    Hum Psychopharmacol; 2018 May; 33(3):e2658. PubMed ID: 29766576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone to Treat Psychotic Disorders.
    Minwalla HD; Wrzesinski P; Desforges A; Caskey J; Wagner B; Ingraffia P; Patterson JC; Edinoff AN; Kaye AM; Kaye AD; Viswanath O; Urits I
    Neurol Int; 2021 Jul; 13(3):343-358. PubMed ID: 34449689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia.
    Lamb YN; Keating GM
    Drugs; 2016 Oct; 76(16):1559-1566. PubMed ID: 27699643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.